Galmed Pharmaceuticals (GLMD) and Dynavax Technologies Corporation (DVAX) Critical Review
Galmed Pharmaceuticals (NASDAQ: GLMD) and Dynavax Technologies Corporation (NASDAQ:DVAX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
Volatility & Risk
Galmed Pharmaceuticals has a beta of 2.55, indicating that its share price is 155% more volatile than the S&P 500. Comparatively, Dynavax Technologies Corporation has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Valuation & Earnings
This table compares Galmed Pharmaceuticals and Dynavax Technologies Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Galmed Pharmaceuticals||$1.00 million||111.68||-$14.30 million||($1.22)||-7.49|
|Dynavax Technologies Corporation||$7.71 million||152.67||-$94.16 million||($2.47)||-8.70|
Galmed Pharmaceuticals has higher revenue, but lower earnings than Dynavax Technologies Corporation. Dynavax Technologies Corporation is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Galmed Pharmaceuticals and Dynavax Technologies Corporation, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dynavax Technologies Corporation||0||0||5||0||3.00|
Galmed Pharmaceuticals presently has a consensus price target of $16.00, indicating a potential upside of 75.05%. Dynavax Technologies Corporation has a consensus price target of $27.80, indicating a potential upside of 29.30%. Given Galmed Pharmaceuticals’ higher possible upside, analysts plainly believe Galmed Pharmaceuticals is more favorable than Dynavax Technologies Corporation.
This table compares Galmed Pharmaceuticals and Dynavax Technologies Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dynavax Technologies Corporation||-1,323.99%||-92.09%||-78.45%|
Institutional & Insider Ownership
8.3% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.2% of Dynavax Technologies Corporation shares are owned by institutional investors. 2.9% of Dynavax Technologies Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Dynavax Technologies Corporation beats Galmed Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
Receive News & Stock Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.